Skip to content

Enterprise value at other companies

Gilead Sciences logo
Gilead SciencesGILD
$187.53B+19.7%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$5.99B+78.4%
Arrowhead Research logo
Arrowhead ResearchARWR
$8.7B+418%
LQD
Liquidia CorporationLQDA
$3.11B+184%
Alkermes logo
AlkermesALKS
$7.12B+41.2%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$12.92B+175%

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s enterprise value?
Mirum Pharmaceuticals, Inc. (MIRM) reported enterprise value of $5.33B in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s enterprise value changed year-over-year?
Mirum Pharmaceuticals, Inc.'s enterprise value increased by 161.8% year-over-year, from $2.03B to $5.33B.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s enterprise value?
Over 5 years (2020 to 2025), Mirum Pharmaceuticals, Inc.'s enterprise value has grown at a 57.5% compound annual growth rate (CAGR), from $396.12M to $3.84B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.